Published in Gastroenterology on April 09, 2013
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol (2016) 1.32
Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol (2014) 1.05
Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol (2015) 0.94
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol (2015) 0.93
Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes (2013) 0.88
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med (2016) 0.86
Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol (2014) 0.83
Change in Quality of Life for Patients with Irritable Bowel Syndrome following Referral to a Gastroenterologist: A Cohort Study. PLoS One (2015) 0.83
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol (2014) 0.82
The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. J Neurogastroenterol Motil (2016) 0.79
Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands. J Med Chem (2016) 0.78
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
Novel therapeutic agents in neurogastroenterology: advances in the past year. Neurogastroenterol Motil (2014) 0.77
Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities. J Med Chem (2015) 0.77
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
Irritable bowel syndrome: current and emerging treatment options. P T (2014) 0.75
Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Ther Clin Risk Manag (2016) 0.75
Importance of rectal urgency in childhood irritable bowel syndrome. J Neurogastroenterol Motil (2014) 0.75
The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol (2017) 0.75
Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clin Gastroenterol Hepatol (2017) 0.75
Post-Infectious Irritable Bowel Syndrome. Curr Gastroenterol Rep (2017) 0.75
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Drug Des Devel Ther (2017) 0.75
Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel) (2017) 0.75
Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea. Clin Exp Gastroenterol (2017) 0.75
Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea. P T (2017) 0.75
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
Endoscopic full-thickness plication for the treatment of gastroesophageal reflux disease: A randomized, sham-controlled trial. Gastroenterology (2006) 1.94
Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med (2016) 1.82
Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther (2004) 1.55
American Gastroenterological Association medical position statement on constipation. Gastroenterology (2013) 1.44
Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology (2009) 1.33
Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial. Gastrointest Endosc (2005) 1.12
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother (2011) 1.03
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial. Gastrointest Endosc (2004) 0.96
Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol (2009) 0.95
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med (2012) 0.94
Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World J Gastroenterol (2006) 0.93
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol (2015) 0.93
A novel endoscopic full-thickness plicator for the treatment of GERD: A pilot study. Gastrointest Endosc (2003) 0.92
Opioid-induced bowel dysfunction. Curr Gastroenterol Rep (2013) 0.90
Glutamate mediates an excitatory influence of the paraventricular hypothalamic nucleus on the dorsal motor nucleus of the vagus. J Neurophysiol (2002) 0.88
Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes (2013) 0.88
The economic impact of irritable bowel syndrome in a managed care setting. J Clin Gastroenterol (2002) 0.87
Involvement of glutamate in gastrointestinal vago-vagal reflexes initiated by gastrointestinal distention in the rat. Auton Neurosci (2003) 0.86
Lateral hypothalamus modulates gut-sensitive neurons in the dorsal vagal complex. Brain Res (2003) 0.86
Tegaserod does not alter fasting or meal-induced biliary tract motility. Am J Gastroenterol (2004) 0.85
The central nucleus of the amygdala modulates gut-related neurons in the dorsal vagal complex in rats. J Physiol (2003) 0.84
Complementary and alternative medicine for the irritable bowel syndrome. Gastroenterol Clin North Am (2011) 0.84
Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. Soc Sci Med (2009) 0.83
Complementary and Alternative Medicine Use Is Prevalent Among Patients with Gastrointestinal Diseases. Dig Dis Sci (2015) 0.83
Spasm, nutcracker, and IEM: real or manometry findings? J Clin Gastroenterol (2008) 0.81
Rifaximin for the treatment of irritable bowel syndrome. Expert Opin Pharmacother (2012) 0.81
Vagal motor neurons in rats respond to noxious and physiological gastrointestinal distention differentially. Eur J Neurosci (2002) 0.80
Endoscopic full-thickness plication for the treatment of GERD: Five-year long-term multicenter results. Surg Endosc (2007) 0.80
Irritable bowel syndrome: evaluation and treatment. Gastroenterol Clin North Am (2003) 0.80
Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol (2017) 0.80
Galanin inhibits gut-related vagal neurons in rats. J Neurophysiol (2003) 0.79
Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience. Drug Discov Today (2011) 0.78
Effect of preoperative intravenous pantoprazole in elective-surgery patients: a pilot study. Dig Dis Sci (2008) 0.78
Treatment Options for Primary Constipation. Curr Treat Options Gastroenterol (2004) 0.77
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. Int J Antimicrob Agents (2012) 0.77
GRP mediates an inhibitory response of gut-related vagal motor neurons to PVN stimulation. Peptides (2002) 0.77
Motility disorders of the colon and rectum. Curr Opin Gastroenterol (2013) 0.76
Diagnosing irritable bowel syndrome: no more million dollar work-up? Clin Gastroenterol Hepatol (2013) 0.76
A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia. J Antimicrob Chemother (2013) 0.76
Update: a 54-year-old woman with constipation-predominant irritable bowel syndrome. JAMA (2008) 0.75
Ethics and industry-sponsored research. CMAJ (2002) 0.75
The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol (2012) 0.75
Fecal Impaction in the Emergency Department: An Analysis of Frequency and Associated Charges in 2011. J Clin Gastroenterol (2016) 0.75
Ethical issues in research in complementary and alternative medicine. JAMA (2004) 0.75
Developmental toxicity of the HMG-CoA reductase inhibitor (PPD10558) in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol (2011) 0.75
Corrigendum: Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol (2017) 0.75
Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder: US Trends From 2006 to 2013. J Clin Gastroenterol (2017) 0.75
Questions & answers. I frequently get constipated. How can I prevent this uncomfortable condition? Health News (2003) 0.75
When is it appropriate to use over-the-counter antidiarrheal medication, and when does diarrhea call for a doctor's visit? Health News (2004) 0.75
Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opin Pharmacother (2004) 0.75